Chongqing Genrix Biopharmaceutical Co Ltd
688443
Company Profile
Business description
Chongqing Genrix Biopharmaceutical Co Ltd is a biopharmaceutical company engaged in the research & development, production and sales of antibody drugs. The company's pipeline includes product candidate that targets Autoimmune Diseases, Infectious Diseases, and Oncology.
Contact
No. 699, Maliu Avenue
Area A, Building 2
International Bio City
Banan District
Chongqing401338
CHNT: +86 2361758666
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
984
Stocks News & Analysis
stocks
Meta earnings: Early look at Muse adoption impresses investors
We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.
stocks
Tesla earnings: Shares fall on slower deliveries growth outlook; Raising valuation
Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,905.80 | 11.30 | -0.13% |
| CAC 40 | 7,782.82 | 28.44 | -0.36% |
| DAX 40 | 25,181.65 | 190.10 | -0.75% |
| Dow JONES (US) | 52,215.16 | 652.82 | -1.23% |
| FTSE 100 | 10,690.36 | 34.67 | -0.32% |
| HKSE | 23,093.37 | 158.69 | 0.69% |
| NASDAQ | 25,955.34 | 53.52 | -0.21% |
| Nikkei 225 | 62,693.16 | 214.68 | -0.34% |
| NZX 50 Index | 13,733.93 | 12.91 | -0.09% |
| S&P 500 | 7,623.68 | 39.75 | -0.52% |
| S&P/ASX 200 | 8,795.20 | 2.00 | 0.02% |
| SSE Composite Index | 3,690.48 | 32.45 | 0.89% |